August 13, 2025

From Gila Monster Venom to Life-Saving Drugs

Why Research Funding Must Embrace the Unexpected

How the most groundbreaking medical discoveries emerge from the most unlikely places, and what this means for grant funding strategies

When Daniel Drucker acquired a Gila monster from the Utah Zoo's breeding program in the late 20th century, he wasn't trying to develop the world's most talked-about diabetes and weight-loss medication. He was simply following a scientific hunch about lizard venom proteins. Today, that "simple hunch" has revolutionized diabetes care and obesity treatment through drugs like Ozempic and Wegovy, medications that generate billions in revenue and transform millions of lives.

The Hidden Pattern of Medical Breakthroughs

The path from Gila monster venom to GLP-1 agonists reveals something profound about how real scientific progress works. Drucker wasn't setting out to solve the obesity crisis, he was investigating basic biological mechanisms. Yet his curiosity-driven research has had more impact on global health than thousands of targeted studies with more obvious applications.

This pattern repeats throughout medical history:

• Lisinopril, one of the world's top-selling blood pressure medications, emerged from studying Brazilian viper venom, research that initially had nothing to do with cardiovascular disease
• Cytarabine, a WHO Essential Medicine for treating leukemia, was inspired by ancient Caribbean sponges defending themselves from foreign DNA
• Tozuleristide, a promising cancer imaging tool, came from studying deathstalker scorpion venom, research that began with basic toxicology, not oncology

Each of these discoveries required researchers to venture into seemingly unrelated territories, following intellectual curiosity rather than predetermined outcomes.

The Innovation Paradox in Grant Funding

The most transformative discoveries often emerge from projects that would struggle to secure funding under current merit review systems.

Imagine Drucker submitting a grant proposal today titled "Investigating Gila Monster Venom Proteins for Potential Therapeutic Applications." How would reviewers respond to:

• Unclear commercial potential
• No obvious connection to existing treatment paradigms
• High risk of "failure" (most venom studies don't yield drugs)
• Difficult to measure short-term impact

Traditional funding metrics, publication counts, citation indices, immediate clinical relevance, would likely work against such proposals. Yet these are precisely the investigations that generate paradigm shifts.

Why Current Funding Models Limit Discovery

The Predictability Trap: When funding bodies prioritize projects with clear, measurable outcomes, they inadvertently select against the kind of open-ended investigation that leads to breakthrough discoveries. Drucker's Gila monster research had no guaranteed deliverables, only questions worth pursuing.

The Relevance Fallacy: Direct relevance to current problems seems logical, but it assumes we already know where solutions will come from. The researchers studying sea sponge biology weren't trying to cure leukemia, yet their work became essential to cancer treatment.

The Timeline Mismatch: Transformative research operates on different timescales than funding cycles. The journey from venom protein identification to FDA-approved medication took decades, far longer than typical grant periods.

A New Framework for Exploratory Funding

1. Curiosity-Driven Portfolios

Allocate a significant percentage of funds to projects driven by fundamental questions rather than predetermined applications. These investigations often generate the most surprising, and valuable, insights.

2. Cross-Disciplinary Pollination

The most innovative discoveries happen at the intersection of fields. Encourage collaborations between seemingly unrelated disciplines: toxicologists and endocrinologists, marine biologists and oncologists, computer scientists and anthropologists.

3. Failure-Tolerant Funding

Create grant categories where "negative" results are valued equally with positive ones. The path to breakthrough discoveries is littered with failed hypotheses that nonetheless advance understanding.

4. Extended Timeline Support

Establish funding mechanisms that support long-term investigation, allowing researchers to follow promising leads even when they diverge from original proposals.

The Role of AI in Supporting Serendipitous Discovery

Modern AI-powered platforms like Atom Grants can help identify unconventional funding opportunities that traditional searches might miss. By analyzing patterns across diverse funding sources, AI can surface grants that support:

• Basic research with unexpected applications
• Cross-disciplinary collaborations
• High-risk, high-reward investigations
• Long-term exploratory studies

The goal isn't to predict which unusual projects will succeed, it's to ensure that genuinely innovative research has pathways to support.

Beyond Immediate Impact: Investing in Scientific Serendipity

The Gila monster story teaches us that the most profound medical advances often come from researchers who dare to ask unusual questions in unexpected places. As research administrators, we have the power to either nurture this kind of investigation or inadvertently suppress it through narrow funding criteria.

Every time we fund a project studying "irrelevant" animal behavior, investigating "useless" biochemical pathways, or exploring "impractical" theoretical questions, we're investing in potential breakthroughs that we can't yet imagine.

The next revolutionary treatment might be hiding in the venom of a creature we consider dangerous, the defensive mechanisms of an ancient organism, or the behavior of a species we've never studied. But we'll only find it if we're brave enough to look.

Ready to discover unconventional funding opportunities for groundbreaking research? Explore how Atom Grants can help you identify support for the next generation of transformative discoveries.